Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Comprehensive decision support tool (DST) in breast cancer: Automated National Comprehensive Cancer Network (NCCN) guidelines linked to living systematic literature review (SLR).

Peter A. Kaufman, Anna Forsythe, Rozee Liu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13676

e13676 Background: An SLR of interventional clinical trials projects > 7,500 publications in 2024, alongside > 6 NCCN updates and numerous FDA appro...

Final clinical and molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion: NCT00626990.

Martin J. van den Bent, Sara C. Erridge, Michael A. Vogelbaum et al. Jun 01, 2025 pp. 2002-2002 10.1200/jco.2025.43.16_suppl.2002

2002 Background: The 1st and 2 nd interim analyses of the CATNON trial on anaplast...

The differential effect of stromal genes on gemcitabine/nab-paclitaxel (GN) and GN/cisplatin (GCN) outcomes in advanced pancreatic adenocarcinoma (aPDAC).

Himil Mahadevia, Sharon Wu, Robert R. McWilliams et al. Jun 01, 2025 pp. 4166-4166 10.1200/jco.2025.43.16_suppl.4166

4166 Background: GN is a front-line therapy for aPDAC. A Phase I/II study demonstrated that GCN has a higher overall response rate and median overall surv...

Real-world safety and effectiveness of trastuzumab deruxtecan (T-DXd) in HER2-overexpressing malignancies: A single-center retrospective study.

Sunny Shengyuan Cai, Kirstin Binz, Sanjana Mullangi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15577

e15577 Background: HER2-overexpressing cancers represent a distinct group of malignancies. Based on the DESTINY-PanTumor02 trial, the FDA recently approve...

Heterogeneity in epithelioid hemangioendothelioma (EHE): Insights into common and organ-specific tumor pathways.

Tom Wei-Wu Chen, Chia-Lang Hsu, Wen-Hsuan Yu et al. Jun 01, 2025 pp. 11565-11565 10.1200/jco.2025.43.16_suppl.11565

11565 Background: EHEs are ultra-rare sarcomas that can arise from various organs, with the primary site being an important prognostic factor. We hypothes...

Genomic landscape of lung cancer in India: Insights from a precision oncology perspective.

Vinu Sarathy, Bharatsinha Baburao Bhosale, Rajesh Saoji et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20080

e20080 Background: Lung cancer is the second most common cancer with a high mortality rate. Understanding its genomic landscape is crucial for identifying...

Impact of BMI on CDK4/6 inhibitors efficacy and safety in advanced breast cancer: Results from a propensity score matched study—CAMELIA.

Min Tian, Yijia Hua, Qian Liu et al. Jun 01, 2025 pp. 1058-1058 10.1200/jco.2025.43.16_suppl.1058

1058 Background: Body mass index (BMI) is strongly associated with the development and progression of breast cancer. Despite the widespread use of cyclin-...

Association between prostate radiation therapy and survival among patients with metastatic prostate cancer by extent of disease burden.

Peter Soo Palencia, Xiwen Zhao, Keervani Kandala et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17123

e17123 Background: Because of improved oncologic efficacy, external beam radiotherapy (RT) is increasingly used in men with metastatic hormone-sensitive p...

Racial differences in serious immune-related adverse events among cancer patients receiving immune checkpoint inhibitors.

Cho Han Chiang, Xiaocao Xu, Yu-Cheng Chang et al. Jun 01, 2025 pp. 1621-1621 10.1200/jco.2025.43.16_suppl.1621

1621 Background: Immune checkpoint inhibitors (ICIs) are associated with an increased risk of adverse events (irAEs). We a...

Differences in insurance status among Asian Americans with cancer: A disaggregated analysis by ethnic subgroup.

Lilac Nguyen, Isabella Nguyen, Emily Feng et al. Jun 01, 2025 pp. 1529-1529 10.1200/jco.2025.43.16_suppl.1529

1529 Background: Asian Americans, the fastest-growing racial/ethnic group in the U.S., experience significant variation in barriers to cancer care access,...

A retrospective observational analysis examining liquid biopsies with tissue biopsies in patients with advanced non-small cell lung cancer.

Alix Taylor Rosenberg, Pratik Shah, Nagashree Seetharamu Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15049

e15049 Background: Non-small cell lung cancer (NSCLC) is genetically diverse, harboring mutations targetable with FDA-approved therapies. Identifying acti...

Geographic, racial and temporal disparities in cancer and respiratory failure mortality in the US: A 24 year retrospective study.

Aqsa Komel, Abdul Qadeer, Sardar Muhammad Imran Khan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20520

e20520 Background: Cancer and respiratory failure (RF) are amongst leading causes of mortality in adults. This study investigates national trends in age-a...

Strategic efforts for optimal outcomes in patients with low anterior resection syndrome (LARS) at the Vanderbilt-Ingram Cancer Center (VICC).

Alexandria Lenyo, Mallory Dunphy, Amala Benny et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15643

e15643 Background: Low anterior resection (LAR) involves surgical resection of the rectum while sparing the anal sphincter and is frequently performed for...

Post hoc analysis of rashes reported in patients (pts) with <i>BRAF</i> -altered relapsed/refractory (r/r) pediatric low-grade glioma (pLGG) treated with the type II RAF inhibitor tovorafenib in FIREFLY-1.

Olaf Witt, Susan N. Chi, Hyoung Jin Kang et al. Jun 01, 2025 pp. 10037-10037 10.1200/jco.2025.43.16_suppl.10037

10037 Background: Targeted therapies have become a mainstay in the treatment of pLGG. While effective, toxicities, including cutaneous adverse events (AEs...

Effect of IV magnesium supplementation in reducing adverse cisplatin associated kidney outcomes.

Ekta Panjrolia, Bhaumik Patel, Scott Silvey et al. Jun 01, 2025 pp. 12123-12123 10.1200/jco.2025.43.16_suppl.12123

12123 Background: Cisplatin is a commonly used chemotherapy agent that is associated with significant nephrotoxicity due to renal tubular cell injury. IV...

A phase 2 study of pemigatinib for pre-treated glioblastoma or other gliomas with activating FGFR1-3 alterations: Results from FIGHT-209.

Enrico Franceschi, Martin J. van den Bent, Marc Sanson et al. Jun 01, 2025 pp. 2003-2003 10.1200/jco.2025.43.16_suppl.2003

2003 Background: FGFR genomic alterations occur in approximately 8% of gliomas. Inhibition of FGFR1-3 with pemigatinib sho...

Targeting HER3 in NSCLC: Leveraging continuing education to bridge the gaps between evidence and practice.

Bharati Hegde, Emily Scully, Jillian L Scavone et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20055

e20055 Background: Treatments that target human epidermal growth factor receptor 3 (HER3) are emerging options for managing patients with non-small cell l...

Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial.

Paula Rodriguez-Otero, Sosana Delimpasi, Albert Oriol et al. Jun 01, 2025 pp. 7510-7510 10.1200/jco.2025.43.16_suppl.7510

7510 Background: LINVO, a BCMA×CD3 bispecific antibody, has shown high efficacy and generally manageable safety in triple-class exposed (TCE: anti-CD38 Ab...

Assessing the impact of policy implementations on treatment duration for patients with locally advanced cervical cancer in a northern province of Argentina.

Angel Gabriel D'Annunzio, Silvina Martinez, Marcela Kober et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23135

e23135 Background: Cervical cancer represents a public health challenge in low and middle-income countries (LMIC). Instituto Misionero del Cancer (IMC) is...

A retrospective analysis of metaplastic triple negative breast cancer response to sacituzumab govitecan and candidacy for targeted therapy.

Shivahamy Maheswaran, Aylin S. Dedeoglu, Andrzej Niemierko et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13015

e13015 Background: Metaplastic breast cancer (MpBC) is a rare, histologically distinct form of breast cancer. Around 90% of MpBC is negative for estrogen...

Association of county-level medical debt and timely treatment initiation among individuals newly diagnosed with cancer.

Jingxuan Zhao, Marcelo C. Perraillon, Roxanne Clark et al. Jun 01, 2025 pp. 11077-11077 10.1200/jco.2025.43.16_suppl.11077

11077 Background: Medical debt is associated with adverse cancer outcomes, including poor survival. However, it is unknown if living in a county with high...

Molecular characteristics, treatment patterns, and survival outcomes in biliary tract cancers: A retrospective analysis from a high-prevalence region.

Ashish Joshi, Udip Maheshwari, Kunal Naishadh Jobanputra et al. Jun 01, 2025 pp. 4109-4109 10.1200/jco.2025.43.16_suppl.4109

4109 Background: Biliary tract cancers (BTC) present significant challenges in management due to their aggressive nature and often late-stage presentation...

Efficacy of Chinese medicine compound Fufang E’jiao Syrupfor symptom burden of cancer-related fatigue in patients with advanced cancer: A randomized clinical trial.

Shanshan Gu, Yun Xu Jun 01, 2025 pp. 12070-12070 10.1200/jco.2025.43.16_suppl.12070

12070 Background: Cancer-related fatigue ( CRF) is often accompanied by a high symptom burden, significantly impacting the quality of life in...

Postoperative assessment using urinary tumor DNA (utDNA) to identify potential candidates for repeat transurethral resection of bladder tumor (re-TURBT) in non-muscle invasive bladder cancer (NMIBC): A retrospective analysis.

Zihan Xue, Yunkai Qie, Hailong Hu et al. Jun 01, 2025 pp. 4587-4587 10.1200/jco.2025.43.16_suppl.4587

4587 Background: The role of routine repeat transurethral resection of bladder tumor (re-TURBT) in managing non-muscle invasive bladder cancer (NMIBC) rem...

Mutational spectrum of cell proliferation genes as early predictive markers for aggressive disease in endometrial cancers.

Aarthi Ramesh, Rohit Ranade, Sandhya Iyer et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15034

e15034 Background: Endometrial cancer (EC) illustrates diverse nucleotide substitution and chromosomal re-arrangement signatures like other cancers. Namel...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page